Sunvozertinib clinical trials
Also written DZD9008.
How each study uses sunvozertinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the sunvozertinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 2 Jul 2025 · ZEGFROVY · NDA 219839 (FDA, Drugs@FDA)
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2024 (6)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 2 |
| 2023 | 3 |
| 2024 | 6 |
| 2025 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 9
Dizal Pharmaceuticals (10) · Hunan Province Tumor Hospital (2) · Shanghai Pulmonary Hospital, Shanghai, China (1) · Shanghai Zhongshan Hospital (1) · Peking Union Medical College Hospital (1) · Sichuan University (1) · Sun Yat-sen University (1) · Fudan University (1)
Often tested with
Tested in the same studies.
Anlotinib (3) · Golidocitinib (1) · Antineoplastic Agents (1) · Crizotinib (1) · Pralsetinib (1) · Larotrectinib (1) · Savolitinib (1) · Pyrotinib (1)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 4
Studies that test sunvozertinib.
- Dec 2026Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCPhase 2 · Tang-Du Hospital
- Dec 2026Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)Not applicable · Peking Union Medical College Hospital
- Feb 2027Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsPhase 2 · Fudan University
- Nov 2027Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.Phase 2 · Sun Yat-sen University
Studies
Open first, then newest update. How each study uses sunvozertinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Assessing an Oral EGFR Inhibitor, DZD9008 in Patients With Advanced Non-small Cell Lung Cancer(NSCLC) With EGFR Mutations (WU-KONG15)RecruitingNot applicablePeking Union Medical College HospitalNCT05559645Written as DZD9008
- Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure:Phase I/IIRecruitingPhase 1/2Sichuan UniversityNCT06195189Written as Sunvozertinib
- Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.RecruitingPhase 2Sun Yat-sen UniversityNCT06563999Written as Sunvozertinib
- Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsRecruitingPhase 2Fudan UniversityNCT07117890Written as sunvozertinib 300mg
- A Phase 3 Study of Sunvozertinib Versus Placebo as Adjuvant Therapy in Patients With Early-Stage Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations or PACC Mutations After Radical SurgeryRecruitingPhase 3Dizal (Jiangsu) Pharmaceutical Co., Ltd.NCT07182682Written as sunvozertinib
- Perioperative Treatment of Sunvozertinib in Stage II-IIIB NSCLCRecruitingPhase 2Tang-Du HospitalNCT06864624Written as Sunvozertinib
- DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29)RecruitingPhase 2Dizal PharmaceuticalsNCT06276283Written as DZD9008 plus Bevacizumab
- Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RWRecruitingPhase 2Hunan Province Tumor HospitalNCT06355609Written as sunvozertinib in combination with Anlotinib
- Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLCRecruitingPhase 2Hunan Province Tumor HospitalNCT06348927Written as sunvozertinib in combination with Anlotinib
- A Study of Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung CancerNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT06182761Written as Sunvozertinib combination with Anlotinib
- A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)Active, not recruitingPhase 3Dizal PharmaceuticalsNCT05668988Written as sunvozertinib
- A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21)CompletedPhase 2Dizal PharmaceuticalsNCT06295432Written as DZD9008+AZD4205
- Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)Active, not recruitingPhase 1/2Dizal PharmaceuticalsNCT03974022Written as Sunvozertinib
- Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation.Active, not recruitingPhase 2Shanghai Pulmonary Hospital, Shanghai, ChinaNCT07274761Written as Sunvozertinib
- Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnPhase 1/2Dizal PharmaceuticalsNCT04148742Written as DZD9008
- Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6)Active, not recruitingPhase 2Dizal PharmaceuticalsNCT05712902Written as Sunvozertinib
- DZD9008 PK Study in Hepatic Impairment SubjectsCompletedPhase 1Dizal PharmaceuticalsNCT06084104Written as DZD9008
- Drug-drug Interactions Between DZD9008 and Itraconazole/CarbamazepineCompletedPhase 1Dizal PharmaceuticalsNCT05418582Written as DZD9008 and carbamazepine
- Assessing the Safety, Tolerability and Pharmacokinetics(PK) of DZD9008 and the Effect of Low-fat Meal on PK of DZD9008 in Healthy Adult ParticipantsCompletedPhase 1Dizal PharmaceuticalsNCT04909242Written as DZD9008
- Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male SubjectsCompletedPhase 1Dizal PharmaceuticalsNCT05159895Written as [14C]-DZD9008
Given beside what is tested · 2 — sunvozertinib is usual care or a partner of the new treatment
- A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1)RecruitingPhase 1Dizal PharmaceuticalsNCT06905197Written as Sunvozertinib
- Study of Oral EGFR Inhibitor DZD6008 Combined With Sunvozertinib in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN8)RecruitingPhase 1/2Dizal PharmaceuticalsNCT07079475Written as Sunvozertinib
Codes
What other systems call sunvozertinib · ClinicalTrials.gg INT002120
- MeSH (NLM) C000731668sunvozertinibOne source NLM
- UNII (FDA) L1Q2K5JYO8SUNVOZERTINIBConfirmed FDA, NLM, Wikidata
- Wikidata Q130051139sunvozertinibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C167205SunvozertinibOne source FDA
- DrugBank DB18925One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000731668 | sunvozertinib | One source NLM |
| UNII (FDA) | L1Q2K5JYO8 | SUNVOZERTINIB | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q130051139 | sunvozertinib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C167205 | Sunvozertinib | One source FDA |
| DrugBank | DB18925 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.